Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S A Factor

Showing results (61-70 of 78) with videos related to

Pageof 8
Sort By:
Neurology|June 11, 2003
Longitudinal outcome of Parkinson's disease patients with psychosisS A Factor, P J Feustel, J H Friedman, et al.
Clinical Neuropharmacology|May 10, 2000
A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesiaR A Hauser, J Friedlander, T A Zesiewicz, et al.
Parkinsonism & Related Disorders|December 3, 2014
Freezing of gait subtypes have different cognitive correlates in Parkinson's diseaseS A Factor, M K Scullin, A B Sollinger, et al.
Neurology|April 12, 2006
Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of NeurologyR Pahwa, S A Factor, K E Lyons, et al.
Neurology|April 4, 2007
Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson diseaseR Pahwa, M A Stacy, S A Factor, et al.
NPJ Parkinson'S Disease|November 30, 2021
Cerebrospinal fluid biomarkers in Parkinson's disease with freezing of gait: an exploratory analysisJ M Hatcher-Martin, J L McKay, A F Pybus, et al.
Parkinsonism & Related Disorders|March 15, 2001
The long-term safety and efficacy of pramipexole in advanced Parkinson's diseaseW J. Weiner, S A. Factor, J Jankovic, et al.
Neurology|October 26, 1999
Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystoniaM F Brin, M F Lew, C H Adler, et al.
NPJ Parkinson'S Disease|May 6, 2016
Common Genetic Variant Association with Altered HLA Expression, Synergy with Pyrethroid Exposure, and Risk for Parkinson's Disease: An Observational and Case-Control StudyG T Kannarkat, D A Cook, J-K Lee, et al.
NPJ Parkinson'S Disease|June 27, 2017
LRRK2 levels in immune cells are increased in Parkinson's diseaseD A Cook, G T Kannarkat, A F Cintron, et al.
Pageof 8

Showing results (61-70 of 78) with videos related to

Sort By:
Pageof 8
Neurology|June 11, 2003
Longitudinal outcome of Parkinson's disease patients with psychosisS A Factor, P J Feustel, J H Friedman, et al.
Clinical Neuropharmacology|May 10, 2000
A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesiaR A Hauser, J Friedlander, T A Zesiewicz, et al.
Parkinsonism & Related Disorders|December 3, 2014
Freezing of gait subtypes have different cognitive correlates in Parkinson's diseaseS A Factor, M K Scullin, A B Sollinger, et al.
Neurology|April 12, 2006
Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of NeurologyR Pahwa, S A Factor, K E Lyons, et al.
Neurology|April 4, 2007
Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson diseaseR Pahwa, M A Stacy, S A Factor, et al.
NPJ Parkinson'S Disease|November 30, 2021
Cerebrospinal fluid biomarkers in Parkinson's disease with freezing of gait: an exploratory analysisJ M Hatcher-Martin, J L McKay, A F Pybus, et al.
Parkinsonism & Related Disorders|March 15, 2001
The long-term safety and efficacy of pramipexole in advanced Parkinson's diseaseW J. Weiner, S A. Factor, J Jankovic, et al.
Neurology|October 26, 1999
Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystoniaM F Brin, M F Lew, C H Adler, et al.
NPJ Parkinson'S Disease|May 6, 2016
Common Genetic Variant Association with Altered HLA Expression, Synergy with Pyrethroid Exposure, and Risk for Parkinson's Disease: An Observational and Case-Control StudyG T Kannarkat, D A Cook, J-K Lee, et al.
NPJ Parkinson'S Disease|June 27, 2017
LRRK2 levels in immune cells are increased in Parkinson's diseaseD A Cook, G T Kannarkat, A F Cintron, et al.
Pageof 8